Survival of patients with bronchogenic carcinoma modified by BCG immunotherapy

Fifty-five patients with stage II and III bronchogenic carcinoma were randomized into one group of 21 treated conventionally, and another group of 34 additionally vaccinated with BCG. Vaccinated patients survived, on average, 11 weeks longer than controls. A lag of about six months existed before consistent differences became apparent.